Serodeconversion of HIV antibody-positive AIDS patients following treatment with V-1 Immunitor
- PMID: 18989372
- PMCID: PMC2577775
- DOI: 10.1155/2009/934579
Serodeconversion of HIV antibody-positive AIDS patients following treatment with V-1 Immunitor
Abstract
It is extremely rare when HIV seropositive adult patients experience spontaneous loss of antibodies, that is, seroreversion. The disappearance of HIV antibodies was occasionally attributed to iatrogenic intervention-serodeconversion. Such interventions include: HAART; oral interferon; Chinese herbal remedies; and therapeutic AIDS vaccines derived from pooled blood. Oral therapeutic, alloimmune AIDS vaccine, V-1 Immunitor (V1), was administered to 60000 HIV-positive Thai patients. The administration of V1 resulted in serodeconversion among 23 individuals. The patient group consisted of 9 females (39%) and 14 males (61%) including two 2-year-old boys. The age range was 2-58 years with mean/median 29/29.3 years. Patients were tested seropositive for HIV at least once before being enrolled on V1. The duration of treatment until discovery of seronegative status ranged between 2 weeks and 15 months with average/median 7.2/8 months. Time to seronegativity was correlated with baseline disease stage (R = 0.62; P = .002). The seronegative status was positively associated with V1-induced undetectable or low viral load (R = 0.65; P = .0008). The odds ratio analysis comparing the outcome of our study with published surveys of diagnostic accuracy of laboratory tests suggested that the probability of HIV antibody testing error was remote (P < .000001). The possible causes responsible for this unusual phenomenon are discussed.
Figures
Similar articles
-
Increased body weight and improved quality of life in AIDS patients following V-1 Immunitor administration.Eur J Clin Nutr. 2004 Jan;58(1):110-5. doi: 10.1038/sj.ejcn.1601756. Eur J Clin Nutr. 2004. PMID: 14679375
-
Effect of an oral therapeutic HIV-1 vaccine on AIDS patients with CD4 count above 250 cells/mm3.Acta Virol. 2004;48(2):73-8. Acta Virol. 2004. PMID: 15462281 Clinical Trial.
-
Prolonged survival of end-stage AIDS patients immunized with therapeutic HIV vaccine V-1 Immunitor.Biomed Pharmacother. 2005 Sep;59(8):469-73. doi: 10.1016/j.biopha.2005.07.004. Biomed Pharmacother. 2005. PMID: 16126364 Clinical Trial.
-
[Safer trials of vaccine and gene therapy against HIV].Hokkaido Igaku Zasshi. 1996 Jan;71(1):21-6. Hokkaido Igaku Zasshi. 1996. PMID: 8727371 Review. Japanese.
-
Candidate AIDS vaccines.N Engl J Med. 1995 Nov 16;333(20):1331-9. doi: 10.1056/NEJM199511163332007. N Engl J Med. 1995. PMID: 7566026 Review. No abstract available.
References
-
- Bartlett JG. Medical Management of HIV. Baltimore, Md, USA: Johns Hopkins University; 2003. (Chapter II, HIV Serology).
-
- MacDonald KL, et al. Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Public health and clinical implications. Annals of Internal Medicine. 1989;110(8):617–621. - PubMed
-
- Nakamura RM. Current status of clinical laboratory tests for the human immunodeficiency virus. Journal of Clinical Laboratory Analysis. 1990;4(4):295–306. - PubMed
-
- Gschnait F. HIV (HTLV III/LAV) serology: experiences based on more than 42,000 tests. Wiener Klinische Wochenschrift. 1987;99(15):536–539. (Ger). - PubMed
-
- Montagnier L, et al. Human immunodeficiency virus infection and AIDS in a person with negative serology. The Journal of Infectious Diseases. 1997;175(4):955–959. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical